close

EMA recommends suspending a number of medicines

On the 23rd January 2015, the European Medicines Agency (EMA) recommended the suspension of a number of medicines due to flawed clinical studies, conducted primarily at GVK Biosciences in Hyderabad, India.

It is unfortunate that a clinical research organisation has failed to meet the very strict standards required by the regulatory authorities, however EFPIA recognises that the announcement from the EMA is evidence that the European regulatory system can detect such issues and take prompt action. It demonstrates we have a system that works.